Can-Fite BioPharma Ltd. (CANF)

Every figure this model derived for CANF, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 5,529,000 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 9,440,000 AssetsCurrent 2025-12-31
current liabilities 2,731,000 LiabilitiesCurrent 2025-12-31
equity 5,592,000 StockholdersEquity 2025-12-31
interest expense 284,000 InterestExpenseNonoperating 2025-12-31
ocf -8,949,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 405,000 Revenues 2025-12-31
sbc 340,000 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up CANF on one particular measure came for.

RatioValue
cash operating margin-2366.91
current ratio4.06
current ratio reported3.46
deferred revenue growth0.0
dilution pct127.09
fcf margin-2210.12
interest cover-35.04
operating margin-2456.79
revenue growth-39.91
revenue growth per share-73.54
roic-12476.98
rpo growth0.0
rule of 40-2496.7
sbc pct revenue83.95

What to be careful about

What this model itself distrusts about CANF's figures. Written by the derivation as it ran, not added afterwards.